[Proton pump inhibition: more than only reflux therapy].
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000453:epidemiology; D002637:Chest Pain / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D000077144:Clopidogrel; D015897:Comorbidity; D018849:Controlled Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D064750:Rabeprazole; D055502:Secondary Prevention; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D000077144:Clopidogrel; D009853:Omeprazole; D013988:Ticlopidine